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APOE-dependent PET patterns of brain
activation in Alzheimer disease
N. Scarmeas, MD; K.E. Anderson, MD; J. Hilton, PhD; A. Park; C. Habeck, PhD; J. Flynn;
B. Tycko, MD, PhD; and Y. Stern, PhD
Abstract—Using H2
15O PET, the authors imaged 13 patients with Alzheimer disease (AD) while performing a serial
nonverbal recognition memory task. Patterns of brain activation differed as a function of APOE genotype: 4 carriers
exhibited lower activation in the left lingual gyrus and higher activation in left cuneus, precuneus, parahippocampal, and
right precentral gyrus. The APOE genotype seems to play a role in cerebral physiologic activity even after onset of clinical
manifestations of AD.
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Although the presence of the 4 allele has been asso-
ciated with earlier age of disease onset, its relation
to different Alzheimer disease (AD) clinical and phe-
notypic subtypes is less clear. It is conceivable that
the clinical heterogeneity observed in AD could de-
rive from underlying genetic variability.
Whereas previous studies have investigated the
association between APOE and patterns of brain ac-
tivation in middle-aged and elderly individuals,1 we
explored the effect of the APOE genotype on brain
activation in patients with AD.
Methods. Subjects. This was part of a larger imaging study,
the details of which are described elsewhere.2 Thirteen subjects
with early AD (nine men and four women) who met National
Institute of Neurological and Communication Disorders and
Stroke/Alzheimer’s Disease and Related Disorders Association for
probable AD (reached at a consensus diagnostic conference of neu-
rologists, psychiatrists, and neuropsychologists) were studied. The
patients underwent MRI, appropriate laboratory tests, and exten-
sive neuropsychological evaluation, part of which is shown in table
E-1 (see table E-1 on the Neurology Web site at www.neurology.
org). With the exception of two subjects (one 4 carrier and one
noncarrier) who were taking acetylcholinesterase inhibitors, pa-
tients were not receiving any other CNS-acting medications.
APOE or PET activation results did not play any role in the
diagnostic process.
Cognitive task. Because APOE-related differential activation
during memory tasks has been previously reported1 and because
nonverbal memory deficits are among the earliest clinical features
of AD, we chose a nonverbal episodic memory task for the neuro-
imaging component of this study. It comprised two conditions
(figure, A).
1. A low demand condition (LD), in which a single shape (differ-
ent each time) was presented during the encoding phase. Dur-
ing the recognition phase, either the same shape as the encod-
ing phase or a nonfamiliar foil was presented. Subjects were
instructed to make a “new” or “old” response for each probe
item by pressing one of two microswitches.
2. A titrated demand (TD) condition involved a serial presenta-
tion of several shapes during the encoding phase. The number
of shapes was determined in a training session on the day
preceding the PET scan, during which shape list size was
adjusted in a staircase manner such that recognition accuracy
was ~75% for each subject. The recognition phase of the TD
condition involved presentation of shapes studied during the
preceding study phase intermixed with nonfamiliar foils.
PET scan acquisition and data processing. Multiple trials of
each condition were acquired during scanning. For each scan, a
bolus of 30 mCi H2
15O was injected IV, and nonquantitative
counts (relative cerebral blood flow [rCBF]) were obtained. Two
30-second scan frames (which were subsequently averaged) were
acquired in two-dimensional mode. The SPM99 program was used
to implement realignment, spatial transformation, smoothing (iso-
tropic, Gaussian kernel [full width at half-maximum  12 mm]),
and proportional scaling by global mean.
General linear model design. Multiple regression analyses
were performed at each voxel with rCBF as the dependent vari-
able. Independent variables were 1) the cognitive task condition
(TD vs LD); 2) the APOE genotype (dichotomous form, presence vs
absence of an 4 allele); and 3) the cognitive task condition 
APOE interaction. Our primary interest was the statistical signif-
icance of the condition  APOE interaction effect, which speaks to
the hypothesis that functional activation (TD rCBF after subtract-
ing out LD rCBF related to basic sensory and motor processing)
differs between 4 allele carriers and noncarriers. The false-
positive rate was controlled at   0.05 per map (Bonferroni
corrected for the number of resolution elements).
Results. Demographic/behavioral. Four (of nine) men
and two (of four) women were 4 carriers (p  0.85). All
patients had early AD: mean modified Mini-Mental State
Examination score was 46 of 57 (corresponding to a Fol-
stein Mini-Mental State Examination score of ~24; see ta-
ble E-1 on the Neurology Web site at www.neurology.org).
Although age did not differ between the groups (p  0.09),
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two 4 carriers had early age of disease onset (symptoms
starting at ages 45 and 53 years), resulting in 4 carriers
being on average 10 years younger. Because patients with
early-onset AD are considered by many to represent a sep-
arate group not only in terms of age but also in terms of
many other clinical or biologic measures, we explored the
effect of removing the early-onset patients from the 4
carrier group (which resulted in almost identical age dis-
tributions in both APOE groups): the imaging analysis re-
sults were unchanged. Education and neuropsychological
performance did not differ statistically among the groups.
To further ensure that the two groups were cognitively
equivalent, we included Selective Reminding Test delayed
recall performance as a covariate in supplementary imag-
ing analyses: the results were similar. The following shape
list sizes were used during the TD condition: 2 (two sub-
Figure. (A) Nonverbal memory task.
Shape list size varied for the titrated
demand condition so that each patient’s
performance was ~75% accurate. For
presentation purposes, a list size of
three shapes during the titrated de-
mand condition is illustrated here. Dur-
ing study phases, subjects were exposed
to each stimulus for 5 seconds, while a
6-second response time limit was im-
posed during the recognition phase. (B)
Graphs plot relative cerebral blood flow
(rCBF) activation for the two groups in
regions where global maxima of signifi-
cance were noted. Note the clear rCBF
separation between the 4 carriers and
noncarriers in these two regions. *The
number of points in the graphs is less
than the number of subjects because of
close proximity of some activation val-
ues, which makes them appear as single
points.
Table Areas where significant associations between brain activation and APOE (presence vs absence of 4) were detected (p  0.05








explained) Location (Brodmann area)x y z
Areas where ε4 carriers exhibit
lower rCBF activation
28 64 3 7.7 19 0.84 Left lingual gyrus (19)
Areas where ε4 carriers exhibit
higher rCBF activation
18 76 33 6.8 8 0.80 Left cuneus (7)
50 8 34 6.6 40 0.80 Right precentral gyrus (6)
38 43 1 5.6 3 0.74 Left parahippocampal gyrus (19)
18 56 45 5.4 3 0.72 Left precuneus (7)
rCBF  relative cerebral blood flow.
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jects), 3 (four subjects), 4 (one subject), 5 (two subjects), 6
(three subjects), and 9 (one subject).
PET data. Compared with the subjects without the 4
allele, 4 carriers exhibited significant deactivation in the
left lingual gyrus (see table and figure, B; also see figure
E-1 on the Neurology Web site at www.neurology.org). At
the same time, 4 carriers manifested significantly higher
activation in left cuneus, precuneus, right precentral, and
parahippocampal gyri.
Discussion. The relation of APOE to different AD
clinical and phenotypic subtypes is debatable. APOE-
related clinical heterogeneity after AD onset is sup-
ported by observations reporting that presence of the
4 allele is associated with increased risk for psycho-
sis,3 less risk for development of extrapyramidal
signs,4 lower rates of cognitive decline, and lower
mortality.4 AD patients with the 4 allele have also
been reported to carry increased -amyloid and neu-
rofibrillary tangles.5 There is controversy regarding
APOE effects on brain tissue atrophy with some
structural MRI studies reporting no APOE-related
differences in hippocampal volumes,6 whereas others
have reported greater atrophy in medial temporal
structures in AD patients carrying the 4 allele.7
Similarly, resting functional imaging studies after
onset of AD have reported mixed results with some
reporting decreased,8 increased,9 or unchanged10 ce-
rebral blood flow or metabolism for the 4 carriers.
We detected an association between APOE geno-
type and cerebral physiologic activity during cogni-
tive activation. This was not a function of differential
effort because memory task difficulty was experi-
mentally equated in the two APOE groups. The de-
tected activation differences indicate altered memory
processing in AD patients with the 4 allele despite
the common underlying pathology. The results argue
for an APOE-dependent neurophysiologic heteroge-
neity among subjects with AD even after the onset of
clinical manifestations of the disease.
Areas with differential activation in the 4 carri-
ers may reflect malfunctioning (taking the form of
either overactivation or deactivation) because of
more severe AD pathologic involvement for 4 carri-
ers in these regions (i.e., parahippocampal gyrus).
Alternatively, some of these regions may still be
spared by AD pathology (i.e., precentral gyrus) and
recruited for task performance by 4 carriers because
of more severe pathologic involvement in other re-
gions. It is also possible that differential activation is
not directly related to the degree or localization of
pathology but reflects APOE-related cerebral physio-
logic heterogeneity.
This study has limitations. Because the PET scan-
ning session encompassed the encoding and recogni-
tion phase of the task, exact APOE-related
neuroanatomic localization for each cognitive process
is not possible. Because no arterial sampling was
performed, we had to rely on relative flow values
rather than absolute quantification of the activa-
tions. This study included white, highly educated pa-
tients recruited from a university-based dementia
referral center, which might limit generalizability to
the population. Finally, the small number of partici-
pants may have limited power to detect significant
age and cognitive differences between carriers and
noncarriers; therefore, results should be replicated
with a larger sample size.
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